Udayan Guha, M.D.,Ph.D. Email and Phone Number

• Investigator and Head, Cancer Signaling Networks Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH.- Bench-to-bedside-and-back laboratory research investigating mechanisms of resistance to targeted therapies and tumor heterogeneity. Conducted mass spectrometry-based proteomics and proteogenomics studies in pre-clinical models, including mouse models, and patients from clinical studies.• Principal Investigator (Investigator-initiated clinical studies) of the following clinical studies.- A pilot study of local ablative therapy for treatment of oligoprogressive, EGFR-mutated, non-small cell lung cancer (NSCLC) after treatment with Osimertinib (Phase 2 study; Clinical Trial Agreement with AstraZeneca).- A pilot study of inpatient hospice with procurement of tissue on expiration in thoracic malignancies. (Rapid autopsy study, established first time at the NCI)- Tissue procurement and natural history study of patients with non-small cell lung cancer, small cell lung cancer, extrapulmonary small cell cancer, pulmonary neuroendocrine tumors, and thymic epithelial tumors. (First Natural History study for Thoracic Malignancies at the NCI)- Pilot trial of molecular profiling and targeted therapy for advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic malignancies - Associate Investigator of multiple clinical studies in Thoracic and GI Malignancies Branch at the NCI- 2011-2020. – most Immunotherapy studies

• Study physician for 1) A Phase ½ single arm open-label clinical trial of TC-510 in patients with advanced mesothelin-expressing cancer and 2) A Phase ½ single arm open-label clinical trial of gavocabtagene autoleucel (Gavo-cel) in patients with advanced mesothelin-expressing cancer• Provide guidance and collaborate with the Translational Medicine team for translational studies on the on-going drug products. • Provide guidance and collaborate with the Discovery Team for IND-enabling studies at TCR2 Therapeutics for pre-clinical assets.• Develop clinical developmental strategies for additional tumor antigen-directed TRuC T cell therapies that are in pre-clinical development.

Clinical Lead and Study Director/Medical Monitor for the following studies:• A Phase I study of BMS-986299 as monotherapy and in combination with nivolumab and ipilimumab in participants with advanced solid cancers (NLRP3 innate agonist)• A Phase ½ study of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors - IND submission and approval of this first-in-class first-in-human study. Currently enrolling.Clinical lead and protocol development for first-in-human, first-in-class studies for the following assets:• Oral PD-L1 inhibitor • Anti-TIGIT bispecificClinical Lead for the diligence team that evaluated a TIGIT-bispecific antibody from Agenus Inc. that resulted in BMS licensing the asset for further clinical development.

Clinical Fellow- OncologyPostdoctoral Research Fellow, Cancer Biology and Genetics (Laboratory of Dr. Harold Varmus)